Editor’s note: This is not an exhaustive list. Deals are listed in chronological order from most to least recent.
- McKesson signed a deal with the U.S. to be a central distributor of a COVID-19 vaccine and the supplies needed to administer it.
- Moderna signed a deal with the U.S. valued at up to $1.5 billion for 100 million doses of its COVID-19 vaccine candidate.
- Johnson & Johnson signed a more than $1 billion deal with the U.S. for 100 million doses of its investigational COVID-19 vaccine.
- The U.S. signed a deal with Sanofi and GlaxoSmithKline to pay the drugmakers up to $2.1 billion for the development and supply of a COVID-19 vaccine they are partnering on.
- Pfizer and BioNTech signed a $1.9 billion deal with the U.S. to secure up to 600 million doses of BNT162, the two drugmakers’ jointly-developed COVID-19 vaccine candidate.
- Novavax signed a $1.6 billion deal with the U.S. to expedite development of its COVID-19 vaccine.
- Emergent BioSolutions signed a $628 million deal with the U.S. to ramp up its contract development and manufacturing capabilities to expedite the delivery of COVID-19 vaccines.
- AstraZeneca signed a more than $1 billion deal with the U.S. to support increased access to its COVID-19 vaccine.
More articles on pharmacy:
FDA extends remdesivir’s emergency use authorization to all hospitalized COVID-19 patients
Walgreens names former Rite Aid CEO as its new president
Heads roll at FDA after commissioner’s comments on convalescent plasma
